Nwam LLC Increases Stock Position in Danaher Corporation $DHR

Nwam LLC increased its holdings in Danaher Corporation (NYSE:DHR) by 28.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,089 shares of the conglomerate’s stock after buying an additional 4,414 shares during the period. Nwam LLC’s holdings in Danaher were worth $3,827,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of DHR. CMH Wealth Management LLC raised its holdings in Danaher by 7.2% during the 2nd quarter. CMH Wealth Management LLC now owns 27,201 shares of the conglomerate’s stock valued at $5,192,000 after acquiring an additional 1,832 shares during the period. Camelot Portfolios LLC bought a new position in shares of Danaher in the second quarter worth $492,000. Headlands Technologies LLC boosted its holdings in shares of Danaher by 90.5% in the second quarter. Headlands Technologies LLC now owns 2,440 shares of the conglomerate’s stock worth $465,000 after acquiring an additional 1,159 shares during the period. Moore Capital Management LP purchased a new position in shares of Danaher in the second quarter valued at $3,224,000. Finally, Two Sigma Securities LLC purchased a new position in shares of Danaher in the second quarter valued at $778,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DHR. Guggenheim dropped their price objective on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. TD Cowen lowered their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. HSBC cut their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Citigroup began coverage on shares of Danaher in a research note on Tuesday, May 26th. They set a “buy” rating and a $230.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $228.91.

Danaher Stock Down 1.0%

DHR stock opened at $213.90 on Tuesday. The company’s 50 day moving average is $200.18 and its 200 day moving average is $192.31. The stock has a market cap of $150.37 billion, a price-to-earnings ratio of 37.99, a price-to-earnings-growth ratio of 2.69 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the business posted $0.77 earnings per share. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. Sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.